In a nutshell The study compared outcomes of utidelone plus capecitabine (Xeloda) versus capecitabine (C) alone in previously treated patients with anthracycline- and taxane-resistant metastatic breast cancer (MBC). The authors found that this combination improved survival compared to C alone in such patients. Some background...
Read MoreConfined or spread disease-Spread to regional lymph nodes Posts on Medivizor
Searching for patients with metastatic breast cancer to trial a targeted therapy
In a nutshell This phase 2 clinical trial is evaluating the safety and effectiveness of targeted therapy TAS-120 (futibatinib) alone or in combination with fulvestrant (Faslodex) in patients with metastatic breast cancer (mBC). The main outcomes to be evaluated will be the response rate and survival without cancer worsening. The details Breast...
Read MoreLong-term outcomes for nivolumab in patients with BRAF-negative advanced melanoma
In a nutshell This study investigated the long-term effectiveness and safety of immunotherapy drug nivolumab (Opdivo) compared to chemotherapy drug dacarbazine (DTIC-Dome) for patients with BRAF-negative advanced melanoma. The study showed that nivolumab significantly increased survival in these...
Read MoreTreating postmenopausal women with HER2- and hormone-receptor positive metastatic breast cancer with lapatinib, trastuzumab and aromatase inhibitor
In a nutshell The study evaluated outcomes of lapatinib (Tykerb), trastuzumab (Herceptin), and aromatase inhibitor (AI) in postmenopausal women with human epidermal growth factor receptor 2-positive (HER2+) and hormone receptor-positive (HR+) metastatic breast cancer (MBC). The authors found that the combination was safe and effective in such...
Read MoreCan immune therapy improve survival in advanced melanoma?
In a nutshell This study looked at the effects after stopping immune therapy in patients with advanced melanoma. They found that responses to treatment lasted long after treatment was stopped. Some background Stage 3 or 4 melanoma refers to a tumor that has spread to lymph nodes or distant organs. At this advanced stage, the cancer...
Read MoreAn examination of pertuzumab and trastuzumab as breast cancer treatment before surgery in a real-life setting
In a nutshell This study examined the effectiveness and safety of the drug combination pertuzumab (Perjeta) and trastuzumab (Herceptin) as a treatment for breast cancer (BC) with positive HER2 (human epidermal growth factor receptor 2) before surgery to remove the tumor in a real-world setting. The data showed that this...
Read MoreCan a combination of dabrafenib and trametinib improve relapse-free survival after removal of stage 3 melanoma?
In a nutshell This study investigated the long-term effectiveness and risks of the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for patients with stage 3 melanoma after tumor removal. It showed that the combination of the two drugs can increase survival without return or spreading of cancer. Some...
Read MoreLooking for patients with advanced breast cancer to trial an experimental drug treatment.
In a nutshell This trial is aiming to examine the effectiveness of an experimental drug, AMXI-5001, in patients with advanced breast cancer. The main outcomes that are to be measured in this trial are side effects and the response to treatment. This trial is going to be carried out in California, Tennessee, and Florida, the United States. The...
Read MoreThe effects of cholesterol-lowering drugs on breast cancer relapse in postmenopausal women under aromatase inhibitor treatment
In a nutshell The study evaluated the link between statin (cholesterol-lowering drugs) use and risks of breast cancer (BC) relapse under adjuvant aromatase inhibitors (AI) therapy in women after their menopause. The main finding was that statin use was related with lower risks of BC relapse in such patients. Some background Women with...
Read MoreDoes pembrolizumab added to chemotherapy before surgery improve the outcomes of patients with early triple negative breast cancer?
In a nutshell The study assessed whether pembrolizumab (Keytruda) could be used in addition to neoadjuvant chemotherapy (NAC; chemotherapy before surgery) to improve the outcomes of patients with early triple-negative breast cancer (TNBC). The study found that more patients treated with pembrolizumab had a complete response. Some...
Read MoreHow common are allergic reactions to different biological therapies in patients with advanced melanoma?
In a nutshell This study compared the frequency of allergic reactions to different doses of three biological therapies in patients with advanced melanoma. The authors found that different doses of the three drugs reduced the number of allergic reactions. Some background Biological therapy has significantly improved treatment results for patients...
Read MorePreserving fertility of patients with early-stage breast cancer
In a nutshell This study looked at fertility preservation (FP) in patients with breast cancer. It found that many patients choose FP before chemotherapy and that most patients have a return of ovulation following treatment. Some background 12% of patients newly diagnosed with breast cancer are under 40 years of age. Preserving fertility is a concern...
Read More